Review and update on inotropes and vasopressors

AACN Advanced Critical Care

Volumn 19, Issue 1, 2008, Pages 5-13

  Cooper, Brad E ^a  

^a HAMOT MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTONIC AGENT; VASOCONSTRICTOR AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; CLASSIFICATION; DRUG INTERACTION; HEMODYNAMICS; HUMAN; INTENSIVE CARE; METHODOLOGY; REVIEW; SHOCK;

CARDIOTONIC AGENTS; CRITICAL CARE; DRUG INTERACTIONS; HEMODYNAMICS; HUMANS; RESPIRATORY DISTRESS SYNDROME, ADULT; SHOCK; VASOCONSTRICTOR AGENTS;

EID: 45149128977     PISSN: 15597768     EISSN: 15597768     Source Type: Journal    
DOI: 10.1097/01.AACN.0000310743.32298.1d     Document Type: Review

References (33)

1. Barrett LK, Singer M, Clapp L. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med. 2007;35:33-40.
2. Pesaturo AB, Jennings HR, Voils SA. Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother. 2006;40:2170-2177.
3. Meadows D, Edwards JD, Wilkins FG, et al. Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med. 1988;16:663-666.
4. Desjars P, Pinaud M, Bugnon D, et al. Norepinephrine has no deleterious renal effects in human septic shock. Crit Care Med. 1989;17:426-429.
5. Gregory JS, Bonfiglio MF, Dasta JF, et al. Experience with phenylephrine as a component of the pharmaco logic support of the septic shock patient. Crit Care Med. 1991;19:1395-1400.
6. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomized trial. Lancet. 200;356:2139-2143.
7. Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med. 2001;29:1526-1531.
8. Friedrich JO, Adhikari N, Herridge MS, et al. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142:510-524.
9. Holmes CL, Walley KR. Bad medicine: low-dose dopamine in the ICU. Chest. 2003;123:1266-1275.
10. Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med. 1997;23:282-287.
11. Duranteau J, Sitbon P, Teboul JL, et al. Effects of epinephrine, norepinephrine, or the combination of norepinephrine and dobutamine on gastric mucosa in septic shock. Crit Care Med. 1999;27:893-900.
12. Meier-Hellmann A, Reinhart K, Bredle DL, et al. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med. 1997;25:399-404.
13. Levy B, Bollart PE, Lucchelli JP, et al. Dobutamine improves the adequacy of gastric mucosal perfusion in epinephrine-treated septic shock. Crit Care Med. 1997;25:1649-1654.
14. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med. 2004;32:1928-1948.
15. LeDoux D, Astiz ME, Carpati CM, et al. Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med. 2000;28:2729-2732.
16. Shoemaker WC, Appel PL, Kram HB, et al. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest. 1988;94:1176-1186.
17. Mihae YU, Levy MM, Smith P, et al. Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled study. Crit Care Med. 1993;21:830-838.
18. Hayes MA, Timmins AC, Ernest HS, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 1994;330:1717-1722.
19. Rivers E, Nguyen B, Havstad S, et al. Early goal directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-1377.
20. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858-873. (Pubitemid 38344143)
21. Micek ST, Roubinian N, Heuring T, et al. Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med. 2006;34:2707-2713.
22. Nguyen HB, Corbett SW, Steele R, et al. Implementation of a bundle of quality indicators for the early management of severe sepsis and septic shock is associated with decreased mortality. Crit Care Med. 2007;35:1105-1112.
23. Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock. Chest. 1993;103:1826-1831.
24. Obritsch MD, Bestul DJ, Jung R, et al. The role of vasopressin in vasodilatory septic shock. Pharmacotherapy. 2004;24:1050-1063.
25. Monrad ES, Baim DS, Smith HS, et al. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation. 1986;73(suppl III):168-174.
26. Grose R, Strain J, Greenberg M, et al. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J Am Coll Cardiol. 1986;7:1107-1113.
27. Biddle TL, Benotti JR, Creager MA, et al. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol. 1987;59:1345-1350.
28. Marcus RH, Raw K, Patel J, et al. Comparison of intravenous amrinone and dobutamine in congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 1990;66:1107-1112.
29. Mager G, Klocke RK, Kux A, et al. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. Am Heart J. 1991;121:1974-1983.
30. Karlsberg RP, DeWood MA, DeMaria AN, et al. Comparative efficacy of short-term intravenous infusions of INOTROPES AND VASOPRESSORS milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Clin Cardiol. 1996;19:21-30.
31. Gage J, Rutman H, Lucido D, et al. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation. 1986;74:367-373.
32. Urestsky BF, Lawless CE, Verbalis JG, et al. Combined therapy with dobutamine and amrinone in severe heart failure. Chest. 1987;92:657-662.
33. Sundram P, Reddy HK, McElroy PA, et al. Myocardial energetics and efficiency in patients with idiopathic cardiomyopathy: response to dobutamine and amrinone. Am Hear J. 1990;119:891-898.